Sequent Scientific Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Rajaram Narayanan

Algemeen directeur

₹31.2m

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	2.6yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Rajaram Narayanan's beloning veranderd ten opzichte van Sequent Scientific's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹165m
Jun 30 2024	n/a	n/a	₹55m
Mar 31 2024	₹31m	₹31m	-₹359m
Dec 31 2023	n/a	n/a	-₹1b
Sep 30 2023	n/a	n/a	-₹1b
Jun 30 2023	n/a	n/a	-₹1b
Mar 31 2023	₹49m	₹49m	-₹1b

Compensatie versus markt: De totale vergoeding ($USD 369.33K ) Rajaram } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 273.81K ).

Compensatie versus inkomsten: De vergoeding van Rajaram is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Rajaram Narayanan (56 yo)

2.6yrs

Tenure

₹31,180,000

Compensatie

Mr. Rajaram Narayanan serves as Managing Director & Chief Executive Officer at Sequent Scientific Limited since April 11, 2022 and also serves as its Director since April 11, 2022. He served as Managing Di...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rajaram Narayanan	MD, CEO & Director	2.6yrs	₹31.18m	geen gegevens
Saurav Bhala	Chief Financial Officer	less than a year	₹6.52m	geen gegevens
Phillip Trott	Secretary	less than a year	₹840.00k	geen gegevens
Ramesh Pillai	Corporate Vice President of Ra Qa and Technical Services	no data	geen gegevens	geen gegevens
Ravi Nair	Executive Vice President of Human Resources & Administration	no data	geen gegevens	geen gegevens
Abhishek Singhal	Head of Investor Relations	no data	geen gegevens	geen gegevens
Vedprakash Ragate	Executive Director	less than a year	geen gegevens	geen gegevens
Prasad Lad	Vice President of HR & Administration	no data	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van 512529 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rajaram Narayanan	MD, CEO & Director	2.6yrs	₹31.18m	geen gegevens
Vedprakash Ragate	Executive Director	less than a year	geen gegevens	geen gegevens
Neeraj Bharadwaj	Additional Non-Executive & Non-Independent Director	4.3yrs	geen gegevens	geen gegevens
Milind Sarwate	Independent Director	4.3yrs	₹2.10m	geen gegevens
Kamal Sharma	Independent Chairman	4.3yrs	₹2.00m	geen gegevens
Fabian Kausche	Additional Non-Executive & Non-Independent Director	3.9yrs	₹500.00k	geen gegevens
Gregory Andrews	Additional Non-Executive Non-Independent Director	4yrs	₹600.00k	geen gegevens
Hari Bodepudi	Non Executive Director	1.3yrs	₹400.00k	geen gegevens

4.0yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 512529 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Sequent Scientific Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director

Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024

Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024

Sequent Scientific Limited Announces Executive Changes

Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024

Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024)

Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024

Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director

Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million

Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion.

Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024

Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API

New major risk - Financial position

Sequent Scientific Limited to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Full year 2024 earnings released: ₹1.44 loss per share (vs ₹4.88 loss in FY 2023)

Sequent Scientific Limited to Report Q4, 2024 Results on May 15, 2024

Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024

Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023)

Sequent Scientific Limited Announces Executive Changes

Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024

Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024

Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023

Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer

Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023

Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023

Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra

Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022)

Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022)

Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director

Price target decreased to ₹149

High number of new and inexperienced directors

Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022)

Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion.

Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022

Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022

First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022)

Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022

Investor sentiment improved over the past week

Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer

Investor sentiment deteriorated over the past week

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022

Price target decreased to ₹170

High number of new and inexperienced directors

Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022

Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO

Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director

CEO, MD & Executive Director recently sold ₹73m worth of stock

Investor sentiment improved over the past week

CEO, MD & Executive Director recently sold ₹84m worth of stock

CEO, MD & Executive Director recently sold ₹23m worth of stock

Investor sentiment deteriorated over the past week

CEO, MD & Executive Director recently sold ₹27m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to ₹197

Insider recently sold ₹5.7m worth of stock

Investor sentiment deteriorated over the past week

Insider recently bought ₹1.4m worth of stock

Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021)

Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021)

Investor sentiment deteriorated over the past week

Insider recently sold ₹17m worth of stock

Insider recently sold ₹17m worth of stock

Full year 2021 earnings released: EPS ₹3.87 (vs ₹2.87 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.3m worth of stock

Third quarter 2021 earnings released: EPS ₹1.54 (vs ₹0.83 in 3Q 2020)

New 90-day high: ₹232

Sequent Scientific Limited to Report Q3, 2021 Results on Feb 03, 2021

Investor sentiment improved over the past week

New 90-day high: ₹214